The literature on risk factors for cardiometabolic diseases showed that lutein might be beneficial for atherosclerosis and inflammatory markers , but there were inconsistent associations with blood pressure , adiposity , insulin resistance , and blood lipids .
CONCLUSIONS Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health .
BACKGROUND The antioxidant lutein is suggested as being beneficial to cardiometabolic health because of its protective effect against oxidative stress , but evidence has not systematic ally been evaluated .
OBJECTIVE We aim ed to evaluate systematic ally the effects of lutein ( intake or concentrations ) on cardiometabolic outcomes in different life stages .
Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in women.
BACKGROUND Growing evidence suggests that lycopene has significant in vitro antioxidant potential .  Lycopene has rarely been tested in prospect i ve studies for its role in cardiovascular disease ( CVD ) prevention . OBJECTIVE We examined the association between plasma lycopene and the risk of CVD in middle-aged and elderly women . DESIGN A prospect i ve , nested , case-control study was conducted in 39 876 women initially free of CVD and cancer in the Women 's Health Study . Baseline blood sample s were collected from 28 345 ( 71 % ) of the women . During a mean of 4.8 y of follow-up , we identified 483 CVD cases and 483 control subjects matched by age , smoking status , and follow-up time .  Plasma lycopene , other carotenoids , retinol , and total cholesterol  were measured . RESULTS In analyses matched for age and smoking , with adjustment for plasma cholesterol , the relative risks ( RRs ) and 95 % CIs of CVD in increasing quartiles of plasma lycopene were 1.00 ( referent ) , 0.78 ( 95 % CI : 0.55 , 1.11 ) , 0.56 ( 0.39 , 0.82 ) , and 0.62 ( 0.43 , 0.90 ) . In multivariate models , the RRs were 1.00 ( referent ) , 0.94 ( 0.60 , 1.49 ) , 0.62 ( 0.39 , 1.00 ) , and 0.67 ( 0.41 , 1.11 ) ; those in the upper compared with the lower half of plasma lycopene had an RR of 0.66 ( 0.47 , 0.95 ) . For CVD , exclusive of angina , women in the upper 3 quartiles had a significant multivariate 50 % risk reduction compared with those in the lowest quartile . The stepwise addition of individual plasma carotenoids did not affect the RRs . CONCLUSIONS Higher plasma lycopene concentrations are associated with a lower risk of CVD in women . These findings require confirmation in other cohorts , and the determinants of plasma lycopene concentrations need to be better understood
The literature on risk factors for cardiometabolic diseases showed that lutein might be beneficial for atherosclerosis and inflammatory markers , but there were inconsistent associations with blood pressure , adiposity , insulin resistance , and blood lipids .
CONCLUSIONS Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health .
BACKGROUND The antioxidant lutein is suggested as being beneficial to cardiometabolic health because of its protective effect against oxidative stress , but evidence has not systematic ally been evaluated .
OBJECTIVE We aim ed to evaluate systematic ally the effects of lutein ( intake or concentrations ) on cardiometabolic outcomes in different life stages .